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Abstract
The major problem in the treatment of acute myeloid leukemia (AML) patients results from multidrug resistance to
administered anticancer agents. Drug resistance proteins, MDR1 and MRP1, which work as drug efflux pumps, can mediate
the multidrug resistance of human leukemia cells. In this study, the mechanisms of resistance to doxorubicin-induced cell
death in human HL60 AML cells were examined.
Continuous exposure of cells to step-wise increasing concentrations of doxorubicin resulted in the selection of HL60/DOX
cells, which expressed about 10.7-fold resistance as compared to parental sensitive cells. The expression analyses of MRP1
and MDR1 drug efflux proteins in doxorubicin-sensitive and -resistant HL60 cells revealed that there was an upregulation of
MRP1 gene in HL60/DOX cells as compared to parental sensitive cells. On the other hand, while there was no expression of
MDR1 gene in parental cells, the expression of MDR1 gene was upregulated in HL60/DOX cells. HL60/DOX cells also
showed cross-resistance to cytosine arabinoside (Ara-c). This resistance was reversed by a combination therapy of Ara-c and
cyclosporine A. However, the expression levels of CD15 and CD16 surface markers were significantly decreased in
HL60/DOX cells.
Keywords: Multidrug resistance, MDR1, MRP1, AML, Doxorubicin, Cytosine arabinoside
Abbreviations: ABC, ATP binding cassette; AML, acute myeloid leukaemia; MDR, multidrug resistance; MDR1,
multidrug resistance gene 1; P-gp, P-glycoprotein; MRP1, multidrug resistance associated gene1; DOX, Doxorubicin; Ara-c,
cytosine arabinoside; Cyc-A, cyclosporine A; HL60/DOX, Doxorubicin-resistant HL60 cells; (IC)50, concentration of any
chemical that inhibit cell growth by 50%; MTT, 3-(4, 5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide; RT-PCR,
reverse transcriptase-polymerase chain reaction
Introduction
Doxorubicin, an antibiotic acting on DNA [1], and
cytosine arabinoside (Ara-c), a cytosine nucleotide
analogue [2], are two important chemotherapeutic
agents used for the treatment of acute myeloid
leukemia (AML). Resistance to chemotherapeutic
agents is an obstacle to the successful treatment of
AML. Several mechanisms may be responsible for this
phenomenon, including failure of the drug to reach
and affect its intracellular target, efflux of the
administered drug from the cells, the inhibition of
drug uptake into the cells or failure of the cells to
undergo apoptosis [3–5].
In leukemias, transporter proteins located in the
plasma membrane are often attributed to multi drug
resistance (MDR). Several transporters have been
identified to have a role in cancer and acute leukemias
during the last decades [6,7]. The ATP-binding
cassette (ABC) proteins represent the largest family of
transmembrane proteins. These proteins bind ATP
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and use the energy to conduct the transport of toxic
chemicals across the cell membranes [3,8].
Multidrug resistance protein (MRP1, 190 kDa
protein), located on the cell membrane and mem-
branes of intracellular compartments [3], can trans-
port a variety of chemicals across those membranes
[9,10]. In MRP1 deleted cell lines greater sensitivity to
the anthracyclines, vinca alkaloids and epipodophyl-
lotoxins has been observed [9,10]. In addition to
MRP1, a 170 kDa plasma membrane glycoprotein,
P-glycoprotein (P-gp), encoded by MDR1 gene
functions as an energy-dependent efflux pump for
chemotherapeutic drugs across the membranes
[10–13]. In cancer cells, intracellular accumulation
of drugs was decreased to sublethal levels by increased
expression of MDR1 gene, resulting in drug resist-
ance. Expression of P-gp is associated with resistance
to several types of antineoplastic agents, mainly
anthracyclines, vinca alkaloids and epipodophyllo-
toxins [14].
The effects of chemotherapeutic agents can be
increased by inhibiting MRP1 and especially P-gp in
multidrug resistant cells. There are several agents that
can inhibit P-gp, including calcium channel blockers,
calmodulin antagonists, surfactants [15] and
especially cyclosporine A. Cyclosporine A is known
to have activity as an inhibitor of both MRP-1 and
P-gp [16–19].
In this study, the involvement of MDR1 and MRP1
genes in the mechanisms of resistance to doxorubicin
and Ara-c in HL60 cells was examined. The data
presented here showed that, treatment with stepwise
increasing concentrations of doxorubicin results in
increased expression of the drug transporter proteins
in resistant sublines, but not in parental cells.
Resistance to anticancer agents can be reversed by a
combination therapy using cyclosporine A.
Materials and methods
Cell line and culture conditions
Human HL60 acute myeloid leukemia cells were
kindly provided by MSKCC, NY, USA. HL60 cells
were maintained in RPMI 1640 growth medium
containing 10% fetal calf serum and 1% penicillin–
streptomycin at 378C in 5% CO2.
Selection of doxorubicin-resistant HL60 cells
Cells maintained in liquid cultures were exposed to
step-wise increasing concentrations of doxorubicin
(30, 50, 70, 90, 110, and 220 nM), which was kindly
provided by Gulhane Military Medical School,
Department of Hematology, Turkey. Subpopulations
of cells those were able to grow in the presence of
220 nM doxorubicin, were then selected, and referred
to as HL60/DOX cells. Then, the inhibitory concen-
tration 50 (IC)50 values of doxorubicin, which
inhibited the growth of the cell population by 50%,
were determined, and compared to parental sensitive
cells as described below.
Measurement of growth by 3-(4,5-dimethylthiazol-2-yl)-
2-5 diphenyltetrazolium-bromide (MTT)
The IC50 values of doxorubicin and/or Ara-c that
inhibited cell growth by 50% were determined from
cell survival plots obtained by MTT as described
previously [20]. Briefly, cells (1 £ 105 cells/well) were
plated into 96-well plates (Costar, Cambridge, MA,
USA) containing 100ml of the growth medium in the
absence or presence of increasing concentrations of
drugs at 378C in 5% CO2 for 24 h. They were then
treated with 0.1 N acidic isopropanol to dissolve the
dark blue crystals of formazan after incubation in the
presence of 5ml of MTT (5 mg/ml) for 4 h. Finally,
the plates were read in an Elisa reader (Ependorf,
Germany) at 570 nm. After that, the IC50 values of the
compound were determined from cell survival plots
as described [21]. Triplicate wells were used for each
treatment.
Isolation of total RNA and RT-PCR
Total RNA was isolated from 1 £ 106 HL60 and
HL60/DOX cells using Trizol reagent (including
guanidium thiocyanate, phenol and sodium citrate) as
described by the manufacturer. Quantification of RNA
was conducted by measuring the absorbance at 260 nm
by UV spectrophotometer. About 5mg of total RNAwas
reverse transcribed using reverse transcriptase. After 1 h
incubation at 428C, the reactions were stopped by 708C
heating for 10 min. The resulting total cDNA was then
used in PCR to measure the mRNA levels of MRP1,
MDR1 and b-microglobulin. The mRNA levels of b-
microglobulin were used as internal control [22]. The
primer sequences and PCR conditions were as follows:
MDR1-forward (50-TACAGTGGAATTGGTGC-
TGGG-30), MDR1-reverse (50-CCCAGTGAAAAA-
ATGTTGCCA-30); MRP1-forward (50-TGAAGGA-
CTTCGTGTCAGCC-30) MRP1-reverse (50-GTCC-
ATGATGGTGTTGAGCC-30) and b-microglobulin-
forward (50-CTTACTGAAGAATGGAGAGAGA-30),
b-microglobulin-reverse (50-CTTACATGTTCTCT-
ATCCCACTT-30) [23]. Using these primers, 2ml of
the reverse transcriptase reaction was amplified for 35
cycles (948C, 30 s; 55–628C, 45 s; 728C, 1 min) using
Taq DNA polymerase (Fermentas, USA), and their
levels were normalized to that of b-microglobulin as
described previously [24].
Determination of differentiation markers
The extent of monocytic differentiation induced in
HL60 cells by doxorubicin was determined by
monitoring of the CD15 and CD16 surface markers
Y. Baran et al.512
D
ow
nl
oa
de
d 
by
 [I
zm
ir 
Yu
ks
ek
 T
ek
no
log
i E
ns
tit
us
u]
 at
 06
:42
 05
 A
ug
us
t 2
01
6 
by flow cytometry. The cell viability was determined
by acridine orange prior to analysis. To detect the
expression of the surface markers, aliquots of 1 £ 106
HL60 cells were harvested at various time points,
centrifuged, and washed twice with 1 £ PBS. The cell
pellet was resuspended in 100ml of PBS and 20ml of
monoclonal antibodies specific for CD15 and CD16
(Becton Dickinson, Mountain View, CA, USA) were
added, and the mixture was incubated in the dark
at 2–88C for 15–30 min. The excess antibody was
washed off with 1 £ PBS, and the pellet was
resuspended in 500ml of 1 £ PBS. The cells were
analyzed by FACScan flow cytometer (Becton
Dickinson, Mountain View, CA, USA).
Results
Long-term exposure to increasing concentrations
of doxorubicin results in the development of resistance
in HL60 cells
To explore the mechanisms involved in the develop-
ment of resistance to doxorubicin-induced apoptosis,
human HL60 cells were exposed to step-wise increas-
ing concentrations of the drug (30–220 nM) for a
period of 12 months, and the sub-clones that expressed
resistance were selected. First, the degree of resistance
was determined by measuring the IC50 values of
doxorubicin at 24 h using MTT assay. As shown in
Figures 1 and 2, HL60 cells that survived upon chronic
exposure to 220 nM doxorubicin, which were referred
to as HL60/DOX expressed about 10.7-fold resist-
ance, as compared to their parental sensitive counter-
parts. The IC50 values of Doxorubicin were found to be
62 and 666 nM for HL60 (Figure 1) and HL60/DOX
(Figure 2) cells, respectively.
Role of MRP1 and MDR1 in resistance to doxorubicin-
induced cell death
First, to examine whether mechanisms by which
HL60/DOX cells express resistance to doxorubicin-
induced cell death involve the up-regulation of MRP1
and MDR1 gene expressions, the mRNA levels of
MRP1 and MDR1 were examined by semi-quantitat-
ive RT-PCR.
In order to determine the expression levels of MRP1
both MRP1 and b-2-microglobulin primers were
amplified in the same PCR mixture which gives an
upper MRP1 (256 bp) and a lower b-2-microglobulin
(120 bp) bands. Figure 3 shows that there was a
parallel increase in mRNA levels of MRP1 in
Doxorubicin resistant HL60/DOX cells as compared
to parental sensitive cells. Quantification analyses of
MRP1 gene expression was conducted by using Vilber
Lourmat Gel Imaging System, 3DI programme.
The results showed that there was around 4.6-fold
increase in expression of MRP1 gene in HL60/DOX
cells as compared to parental cells (Figure 3).
Expression levels of MDR1 gene was also examined
in both HL60/DOX and parental sensitive cells by RT-
PCR. Results revealed that there was no expression of
MDR1 gene in HL60 cells. However, in HL60/DOX
Figure 1. Effects of doxorubicin on the growth of HL60 cells,
in situ. The IC50 concentration of doxorubicin was determined by
MTT assay for HL60 cells as described. The MTT assays were
performed using triplicate samples in at least two independent
experiments. Statistical significance was determined using two-way
ANOVA, and p , 0.001 was considered significant.
Figure 2. Effects of doxorubicin on the growth of HL60/DOX
cells, in situ. The IC50 concentration of doxorubicin was determined
by MTT assay for HL60/DOX cells as described. The MTT assays
were performed using triplicate samples in at least two independent
experiments. Statistical significance was determined using two-way
ANOVA, and p , 0.001 was considered significant.
Figure 3. Expression analyses of MRP1 gene. Expression levels of
MRP1 gene in parental and 30-, 50-, 70-, 90-, 110-, and 220 nM
doxorubicin resistant HL60 cells (lanes 2–8, respectively) were
examined by RT-PCR. b-Microglobulin levels were used as controls
(lanes 2–8, respectively). Lane 1 is DNA ladder.
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D
ow
nl
oa
de
d 
by
 [I
zm
ir 
Yu
ks
ek
 T
ek
no
log
i E
ns
tit
us
u]
 at
 06
:42
 05
 A
ug
us
t 2
01
6 
cells, there was a significant expression of MDR1 gene
(Figure 4). Taken together these results may suggest
that HL60 cells can survive at higher concentrations of
doxorubicin and this resistance can be explained by
overexpression of the MRP1 and MDR1 genes.
HL60/DOX cells showed cross-resistance to Ara-c
Both parental and doxorubicin resistant cells were
treated with increasing concentrations of Ara-c to
examine any possible cross-resistance. MTT cell
proliferation assay revealed that the IC50 values for
Ara-c were 5.75 and 0.034mM for HL60/DOX and
HL60 cells, respectively (Figure 5). There were
around 39 and 76% cell viability in Ara-c treated
HL60 and HL60/DOX cells which shows that
HL60/DOX cell showed cross-resistance to Ara-c as
compared to parental sensitive cells.
Inhibition of MRP1 and MDR1 by cyclosporine A
increases apoptotic effect of Ara-c in HL60/DOX cells
The IC50 values of Ara-c and the combination therapy
of cyclosporine-A (3mM) and Ara-c in HL60/DOX
cells were examined. As shown in Figure 6,
HL60/DOX cells, exposed to cyclosporine-A and
Ara-c, expressed about 54-fold more sensitivity, as
compared to only Ara-c applied counterparts.
The IC50 values of Ara-c alone and cyclosporine-A
in combination with Ara-c were 5.75 and 0.107mM
for HL60/DOX cells, respectively (Figure 6). In
0.1mM Ara-c exposed HL60/DOX cells the cell
proliferation was around 75%, while it was 50% in
0.1mM Ara-c and 3mM cyclosporine A treated cells
which indicate that resistance to anticancer agents in
HL60 cells could be substantially reversed by
cyclosporine A.
Expression of the CD15 and CD16 markers on parental
and doxorubicin-resistant HL60 cells
To examine the variability of CD15 and CD16
expression in parental and doxorubicin resistant AML
cells, flow cytometry was used (Figure 7). The results
revealed that there were 82 and 81% expression of
CD15 and CD16 markers in parental sensitive cells,
respectively. However, the expression levels of CD15
and CD16 markers were decreased to 38 and 28% in
doxorubicin resistant HL60/DOX cells (Figure 7).
Discussion
Multidrug resistance is the main problem in the
treatment of human malignancies. In vitro studies are
often useful for determination of the contributers to
drug-resistance in human cancer cells. Generally, the
genes and the proteins identified in these types of
Figure 4. Expression analyses of MDR1 gene. Expression levels of
MDR1 gene in parental and doxorubicin resistant HL60 cells (lanes
2 and 4, respectively) were examined by RT-PCR. b-Actin levels
were used as controls (lanes 3 and 5 for HL60 and HL60/DOX,
respectively). Lane 1 is DNA ladder.
Figure 5. Effects of Ara-c on the growth of HL60 and HL60/DOX
cells, in situ. The IC50 concentration of Ara-c was determined by
MTTassay for both HL60 (triangle) and HL60/DOX (square) cells
as described. The MTT assays were performed using triplicate
samples in at least two independent experiments. Statistical
significance was determined using two-way ANOVA, and
p , 0.001 was considered significant.
Figure 6. Effects of combination therapy of Ara-c and cyclosporine
A (3mM) on the growth of HL60/DOX cells, in situ. The IC50
concentration of Ara-c (square) and combination therapy of Ara-c
and 3mM Cyc-A (triangle) were determined by MTT assay for
HL60/DOX cells as described. The MTT assays were performed
using triplicate samples in at least two independent experiments.
Statistical significance was determined using two-way ANOVA, and
p , 0.001 was considered significant.
Y. Baran et al.514
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in vitro experimental studies goes well with the in vivo
data [25,26] and the results of the clinical therapy
[23]. Therefore, the application of experimental
results is important for the discovery of new strategies
for treatment of cancer and the prediction of the
response created by cancer cells.
With this aim, HL60 cells were cultured in the
presence of gradually increasing concentrations (up to
220 nM) of doxorubicin over a period of 12 months
to generate doxorubicin-resistant sub-lines of human
AML cells. The first observation from this study was
difficulty in generating doxorubicin resistant HL60
cells which indicate the high efficiency of doxorubicin
in the treatment of AML. Resistant cells were
obtained by stepwise increasing concentrations of
doxorubicin. The next highest drug concentration was
applied to the cells when they could survive and
proliferate at the present concentrations of doxorubi-
cin. By that way HL60 cells could be grown up to
220 nM doxorubicin and referred as HL60/DOX sub
line. Similar approach has been used in various studies
to derive drug-resistant cells starting with parental
sensitive cells. HL60 cells resistant to vincristine
[27,28], to adriamycin [29] and to melphalan [30]
were generated to investigate the resistance mechan-
isms and to reverse the MDR.
Cancer cells often display cross-resistance pheno-
type to structurally and functionally different
anticancer agents that have never been applied.
Cross-resistance to Ara-c in multidrug-resistant cells
has been reported previously by different groups in
vincristine resistant HL60 [27] and P388 cells [31]
and in vincristine and doxorubicin resistant LBR cells
[32]. In this study we also observed that doxorubicin
resistant cells were also resistant to Ara-c. It has been
well shown by Mansson and co-workers that Ara-C
does also work as P-gp substrate in a P-gp-expressing
promyelocytic leukemia subline.
Drug resistance resulting from overexpression of
MRP1 or MDR1 were examined by RT-PCR analyses.
The results have indicated that MRP1 gene expression
was increased in parallel with increasing the levels of
doxorubicin-resistance. On the other hand, while
there was no expression of MDR1 gene in parental
HL60 cells, doxorubicin application resulted in
significant increase in expression of MDR1 gene. Hu
and co-workers also showed upregulation of P-gp after
16 h application of epirubicin, daunorubicin, MX2
and Ara-c to blasts which were shown to be P-
gp negative [33]. Upregulation of P-gp in vincristine
resistant HL60 cells was reported by our group [27].
Weisburg and co-workers also showed that cells
transfected with MDR1 gene containing vector were
more resistant to complement-mediated cytotoxicity
by antibodies against different cell-surface antigens
[34]. Taken together the data suggest that, over-
expression of MRP1 and MDR1 genes in HL60/DOX
cells is at least partially responsible for doxorubicin
and Ara-c resistance in human AML cells.
Therapeutic strategies aiming to overcome drug
resistance is known as reversal of the resistance by
using very specific inhibitors. In this study, inhibition
of MRP1 and MDR1 may be useful in enhancement
cytotoxic effects of Ara-c. In this setting, resistance to
Ara-c can be reversed, at least in vitro, by variety of
resistance reversal agents known as chemosensitizers.
MDR modulators inhibit binding of transport
proteins to anticancer agents resulting in accumu-
lation of drugs in the cell. Apart from reversal
modulators, the antisense oligomers targeted MDR1
Figure 7. Expression analyses of CD15 and CD16 markers. Expression levels of CD15 and CD16 markers were examined by flow
cytometry. Statistical analysis was done using one-way ANOVA, p , 0.001 was considered significant.
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or MRP1 mRNA may also result in decrease and even
loss of resistance, as there will be no transport protein
synthesis. In this work cyclosporine A has been shown
to have inhibitory effects on both transmembrane
proteins. The MTT results showed that there was
76% cell viability in 0.1 mM Ara-c applied
HL60/DOX cells, while it was only around 49% in
0.1mM Ara-c and 3mM cyclosporine A applied cells.
Thus, the sensitivity to Ara-c was increased as the cells
exposed to the combination of drugs which indicates
that MDR1 and MRP1 may somehow be responsible
for Ara-c resistance.
In parallel with these results, MDR protein
expression in malignancies; anticancer agent admin-
istration in combination with cyclosporine A gener-
ated encouraging results. Morgan and co-workers
observed positive outcomes in combination therapy of
carboplatin and cyclosporine A in resistant ovarian
cancer [35], while Kruijtzer and co-workers obtained
similar results with combination therapy of paclitaxel
and cyclosporine A in advanced non-small-cell lung
cancer [36].
CD15 and CD16 are expressed on adult granulo-
cytes and are maintained throughout maturation [37].
CD15 and CD16 surface markers expression analyses
revealed that there were a significant decreases in
expression of CD15 and CD16 markers on
HL60/DOX cells as compared to parental cells thus
shows less maturity of resistant cells.
In summary, the multi-drug resistant HL60/DOX
cell lines may represent a valuable model to identify
drug resistance-associated genes. Further study, both
in vitro and in vivo will hopefully establish the possible
mechanisms of resistance in AML so that the
prevention of the resistance by combination therapies
will be more effective.
Acknowledgements
This study was supported by the research project by
DPT-07-02-K120540-14 grant. We would like to
thank Dr Bahar Baran for her help in preparation of
the manuscript.
References
[1] DeVita VT, Hellman S, Rosenberg SA. Cancer: Principles &
practice of oncology. 7th ed. Philadelphia: Lippincott Williams &
Wilkins; 2005.
[2] Kolitz JE, George SL, Dodge JE. Dose escalation studies of
Ara-C (A), daunorubicin (D) and etoposide (E) with and
without multidrug resistance (MDR) modulation with PSC-
833 (P) in untreated adults with acute myeloid leukemia
(AML) , 60 years: Final induction results of CALGB 9621.
Blood 2001;98:461a, abstract.
[3] Gottesman MM, Fojo T, Bates SE. Multidrug resistance in
cancer: Role of ATP-dependent transporters. Nat Rev Cancer
2002;2:48–58.
[4] Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer.
Mechanisms, reversal using modulators of MDR and the role
of MDR modulators in influencing the pharmacokinetics of
anticancer drugs. Eur J Pharm Sci 2000;11:265–283.
[5] Litman T, Druley TE, Stein WD, Bates SE. From MDR to
MXR: New understanding of multidrug resistance systems,
their properties and clinical significance. Cell Mol Life Sci
2001;58:931–959.
[6] Karp JE. MDR modulation in acute myelogenous leukemia:
Is it dead? Leukemia 2001;15:666–667.
[7] Ross DD. Novel mechanisms of drug resistance in leukemia.
Leukemia 2000;14:467–473.
[8] Borst P, Evers R, Kool M, Wijnholds J. A family of drug
transporters: The multidrug resistance-associated proteins.
J Nat Cancer Inst 2000;92(16):1295–1302.
[9] Doyle LA, Ross DD. Multidrug resistance mediated by the
breast cancer resistance protein BCRP (ABCG2). Oncogene
2003;22:7340–7358.
[10] Leonard GD, Polgar O, Bates SE. ABC transporters and
inhibitors: New targets, new agents. Curr Opin Investig Drugs
2002;3:1652–1659.
[11] Christina L, Linn H, Malin B, Kourosh L, Christer P, Staffan
E. Mechanisms of cross-resistance between nucleoside
analogues and vincristine or daunorubicin in leukemic cells.
Biochem Biophys Res Commun 2004;320:825–832.
[12] Baker EK, Osta A El. The rise of DNA methylation and the
importance of chromatin on multidrug resistance in cancer.
Exp Cell Res 2003;290:177–194.
[13] Scotto KW. Transcriptional regulation of ABC drug transpor-
ters. Oncogene 2003;22:7496–7511.
[14] Dean M, Hamon Y, Chimini G. The human ATP-binding
cassette (ABC) transporter superfamily. J Lipid Res 2001;42:
1007–1017.
[15] Ferry DR, Traunecker H, Kerr DJ. Clinical trials of P-
glycoprotein reversal in solid tumours. Eur J Cancer 1996;
32A:1070–1081.
[16] List AF, Kopecky KJ, Willman CL, Head DR, Persons DL,
Slovak ML, et al. Benefit of cyclosporine modulation of drug
resistance in patients with poor-risk acute myeloid leukemia: A
southwest oncology group study. Blood 2001;98:3212–3220.
[17] Twentyman PR, Versantvoort CH. Experimental modulation
of MRP (multidrug resistance-associated protein)-mediated
resistance. Eur J Cancer 1996;32A:1002–1009.
[18] Misbah Q, Kieran LO, Stacy MF, Nicole AW, William RG,
Hans M, et al. Cyclosporin A is a broad-spectrum multidrug
resistance modulator. Clin Cancer Res 2005;11:2320–2326.
[19] Hirrlinger J, Konig J, Keppler D, Lindenau J, Schulz JB,
Dringen R. The multidrug resistance protein MRP1 mediates
the release of glutathione disulfide from rat astrocytes during
oxidative stress. J Neurochem 2001;76(2):627–636.
[20] Baran Y, Gu¨ndu¨z U, Ural AU. Expression of MDR1 gene in
HL60 cells selected with vincristine. Turk J Cancer 2005;
35(2):88–92.
[21] Piskin O, Ozcan MA, Ozsan GH, Ates H, Demirkan F,
Alacaciogˇlu I, et al. Synergistic effect of imatinib mesylate and
fludarabine combination on Philadelphia chromosome-
positive chronic myeloid leukemia cell lines. Turk J Hematol
2007;24:23–27.
[22] Hirose M. Biology and modulation of multidrug resistance
(MDR) in hematological malignancies. Int J Hematol 2002;
76:206–211.
[23] Filipits M, Suchomel RW, Dekan G, Haider K, Valdimarsson
G, Depisch D, et al. MRP and MDR1 gene expression in
primary breast carcinomas. Clin Cancer Res 1996;2(7):
1231–1237.
[24] Ogretmen B, Schady D, Usta J, Wood R, Kraveka JM, Luberto
C, et al. Role of ceramide in mediating the inhibition of
telomerase activity in A549 human lung adenocarcinoma cells.
J Biol Chem 2001;276:24901–24910.
[25] Chow KU, Nowak D, Kim SZ, Schneider B, Komor M,
Boehrer S, et al. In vivo drug-response in patients with
Y. Baran et al.516
D
ow
nl
oa
de
d 
by
 [I
zm
ir 
Yu
ks
ek
 T
ek
no
log
i E
ns
tit
us
u]
 at
 06
:42
 05
 A
ug
us
t 2
01
6 
leukemic non-Hodgkin’s lymphomas is associated with in vitro
chemosensitivity and gene expression profiling. Pharmacol Res
2006;53:49–61.
[26] Gyorffy B, Serra V, Jurchott K, Abdul-Ghani R, Garber M,
Stein U, et al. Prediction of doxorubicin sensitivity in breast
tumors based on gene expression profiles of drug-resistant cell
lines correlates with patient survival. Oncogene 2005;24:
7542–7551.
[27] Baran Y, Gu¨ndu¨z Y, Ural AU. Cross-resistance to cytosine
arabinoside in human acute myeloid leukemia cells selected for
resistance to vincristine. Exp Oncol 2006;28(2):163–165.
[28] Dong BX, Chen XQ, Wang Z, Liang R, Bai QX, Huang GS,
et al. Difference of gene expression profiles between HL-
60/VCR and HL-60 cells detected by human genome
genechip. J Exp Hematol Chinese Association of Pathophy-
siology 2006;14(3):492–496.
[29] Demidenko ZN, Halicka D, Kunicki J, McCubrey JA,
Darzynkiewicz Z, Blagosklonny MV. Selective killing of
adriamycin-resistant (G2 checkpoint-deficient and MRP1-
expressing) cancer cells by docetaxel. Cancer Res 2005;
65(10):4401–4407.
[30] Pu QQ, Bezwoda WR. Induction of alkylator (melphalan)
resistance in HL60 cells is accompanied by increased levels of
topoisomerase II expression and function. Mol Pharm 1999;
56(1):147–153.
[31] Higashigawa M, Ido M, Kuwabara H, Hori H, Ohkubo T,
Kawasaki H, et al. Membrane transport of 1-b-D-arabinofur-
anosylcytosine and accumulation of 1-b-D-arabinofuranosyl-
cytosine 5’-triphosphate in P388 murine leukemic cells
resistant to vincristine. Leuk Res 1991;15(4):255–262.
[32] Lopes EC, Scolnik M, Alvarez E, Hajos SE. Modulator
activity of PSC 833 and cyclosporin-a in vincristine and
doxorubicin-selected multidrug resistant murine leukemic
cells. Leuk Res 2001;25(1):85–93.
[33] Hu XF, Slater A, Kantharidis P, Rischin D, Juneja S, Rossi R,
et al. Altered multidrug resistance phenotype caused by
anthracycline analogues and cytosine arabinoside in myeloid
leukemia. Blood 1999;93:4086–4095.
[34] Weisburg JH, Curcio M, Caron PC, Raghu G, Mechetner EB,
Roepe PD, et al. The multidrug resistance phenotype confers
immunological resistance. J Exp Med 1996;183:2699–2704.
[35] Morgan RJ, Synold TW, Gandara D, Muggia F, Scudder S,
Reed E, et al. Phase II trial of carboplatin and infusional
cyclosporine in platinum-resistant recurrent ovarian cancer.
Cancer Chemother Pharmacol 2004;54:283–289.
[36] Kruijtzer CM, Schellens JH, Mezger J, Scheulen ME, Keilholz
U, Beijnen JH, et al. Phase II and pharmacologic study of
weekly oral paclitaxel plus cyclosporine in patients with
advanced non-small-cell lung cancer. J Clin Oncol 2002;20:
4508–4516.
[37] Elghetany MT, Lacombe F. Physiologic variations in
granulocytic surface antigen expression: Impact of age,
gender, pregnancy, race, and stress. J Leukoc Biol 2004;75:
157–162.
MDR mechanisms in doxorubicin resistant HL60 cells 517
D
ow
nl
oa
de
d 
by
 [I
zm
ir 
Yu
ks
ek
 T
ek
no
log
i E
ns
tit
us
u]
 at
 06
:42
 05
 A
ug
us
t 2
01
6 
